Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
MyMD Pharmaceuticals, Inc. MYMD
$1.83
+$0.12 (6.40%)
На 18:01, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
70289523.00000000
-
week52high
6.15
-
week52low
0.90
-
Revenue
0
-
P/E TTM
-13
-
Beta
4.47783400
-
EPS
-0.37000000
-
Last Dividend
0.00000000
-
Next Earnings Date
15 мая 2023 г. в 20:00
Описание компании
MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the causes of disease. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines; and to delay aging and increase longevity, as well as treat autoimmune diseases and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic derivative of cannabidiol for treating chronic pain, addiction, and epilepsy. The company was founded in 2014 and is headquartered in Baltimore, Maryland.
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Rivard Paul | A | 225000 | 10000 | 08 дек 2022 г. |
| Silverman Joshua | A | 88775 | 5000 | 26 ноя 2021 г. |
| Silverman Joshua | A | 83775 | 3266 | 24 ноя 2021 г. |
| Silverman Joshua | A | 80509 | 6734 | 24 ноя 2021 г. |
| Rivard Paul | A | 215000 | 15000 | 23 ноя 2021 г. |
| Kaplin Adam | A | 600000 | 600000 | 14 окт 2021 г. |
| Rivard Paul | A | 200000 | 200000 | 14 окт 2021 г. |
| Chapman Christopher C JR | A | 600000 | 600000 | 14 окт 2021 г. |
| Silverman Joshua | A | 600000 | 600000 | 14 окт 2021 г. |
| EAGLE CRAIG | A | 150000 | 150000 | 14 окт 2021 г. |
Новостная лента
ADDING MULTIMEDIA MyMD Pharmaceuticals® to Present Data on Oral TNF-a Inhibitor MYMD-1® at the British Society for Immunology (BSI) Congress 2022
Business Wire
06 дек 2022 г. в 09:40
BALTIMORE--( BUSINESS WIRE )--MyMD Pharmaceuticals, Inc. ® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharmaceutical company developing groundbreaking therapies for the treatment of serious and debilitating autoimmune and inflammatory diseases, is presenting data today at the 2022 British Society for Immunology (BSI) Congress in Liverpool, England. Results from preclinical and clinical studies showed that MYMD-1 was safe and well-tolerated in healthy subjects and significantly reduced inflammation in a mouse model compared to the widely used arthritis treatment etanercept (Enbrel®). These findings support the continued evaluation of MYMD-1® for autoimmune and inflammatory disorders.
What to Know About Buying Penny Stocks on July 11th
PennyStocks
11 июл 2022 г. в 07:00
Here's what you need to know about trading penny stocks on July 11th The post What to Know About Buying Penny Stocks on July 11th appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.